COMPARATIVE EVALUATION OF CLINICAL EFFICACY OF CETIRIZINEIN THE TREATMENT OF CHRONIC URTICARIA AND BIOPHARMACEUTICAL CHARACTERISTICS OF CETIRIZINE IN THE DOSAGE FORM OF DIFFERENT MANUFACTURERS


Cite item

Full Text

Abstract

Results of comparative clinical and biopharmaceutical research of original and generic «cetirizine» used for treatment of chronic urticaria in adults are proposed. The study revealed the advantage of the original drug «cetirizine», which allows it to be recommended for more effective treatment of severe and moderate forms of chronic urticaria. Generic drugs «Parlazin» and «Cetrin» showed a higher efficiency than «Cetirizine-Hexal» and «Zodac». Results of clinical studies correlate with the results of pharmaceutical analysis.

References

  1. Зиртек, НД 42-14183-06.
  2. Зодак, НД 42-12021-06.
  3. ОФС Таблетки, растворение, 42-0003-04.
  4. Парлазин, НД 42-12927-03.
  5. Российский национальный согласительный документ. Крапивница и ангиоотек: рекомендации для практических врачей. - М.: Фармарус Принт Медиа, 2007.
  6. Цетрин, НД 42-3200-01.
  7. Цетиризин-гексал, НД 42-13260-04.
  8. Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. Office of training and communications. Division of communications management the drug information branch, HFD-210, 5600 Fishers Lane Rockville, MD 20857 (1997).
  9. Zuberbier T., Bindslev-Jensen C., Canonica W., et al. // Allergy. 2006. - Vol. 61. - P. 321-331.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Nekrasova E.E., Razvalyaeva A.V., Vergeychik E.N., Gubanova L.B., Malyuzhinskaya N.V., Nekrasova E.E., Razvalyaeva A.V., Vergeichik E.N., Gubanova L.B., Malyuzhinskaya N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 79562 от 27.11.2020 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies